These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19075655)

  • 1. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
    Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
    Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
    Park SB; Lin CS; Kiernan MC
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches.
    Screnci D; McKeage MJ
    J Inorg Biochem; 1999 Oct; 77(1-2):105-10. PubMed ID: 10626361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
    Beijers AJ; Jongen JL; Vreugdenhil G
    Neth J Med; 2012 Jan; 70(1):18-25. PubMed ID: 22271810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies.
    Pellacani C; Eleftheriou G
    Adv Med Sci; 2020 Sep; 65(2):265-285. PubMed ID: 32361484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Staff NP; Cavaletti G; Islam B; Lustberg M; Psimaras D; Tamburin S
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2(Suppl 2):S26-S39. PubMed ID: 31647151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathophysiology of oxaliplatin-induced neurotoxicity.
    Kiernan MC; Krishnan AV
    Curr Med Chem; 2006; 13(24):2901-7. PubMed ID: 17073636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
    Park SB; Goldstein D; Krishnan AV; Lin CS; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC
    CA Cancer J Clin; 2013; 63(6):419-37. PubMed ID: 24590861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced peripheral neurotoxicity.
    Cavaletti G; Marmiroli P
    Expert Opin Drug Saf; 2004 Nov; 3(6):535-46. PubMed ID: 15500413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
    Amara S
    Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
    Chan A; Hertz DL; Morales M; Adams EJ; Gordon S; Tan CJ; Staff NP; Kamath J; Oh J; Shinde S; Pon D; Dixit N; D'Olimpio J; Dumitrescu C; Gobbo M; Kober K; Mayo S; Pang L; Subbiah I; Beutler AS; Peters KB; Loprinzi C; Lustberg MB
    Support Care Cancer; 2019 Oct; 27(10):3729-3737. PubMed ID: 31363906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity of taxanes: symptoms and quality of life assessment.
    Kuroi K; Shimozuma K
    Breast Cancer; 2004; 11(1):92-9. PubMed ID: 14718800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
    Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral nerve damage associated with administration of taxanes in patients with cancer.
    Argyriou AA; Koltzenburg M; Polychronopoulos P; Papapetropoulos S; Kalofonos HP
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):218-28. PubMed ID: 18329278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.
    Kus T; Aktas G; Alpak G; Kalender ME; Sevinc A; Kul S; Temizer M; Camci C
    Support Care Cancer; 2016 May; 24(5):2085-2091. PubMed ID: 26546457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.
    Gamelin E; Gamelin L; Bossi L; Quasthoff S
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):21-33. PubMed ID: 12422305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxane induced neuropathy in patients affected by breast cancer: Literature review.
    De Iuliis F; Taglieri L; Salerno G; Lanza R; Scarpa S
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):34-45. PubMed ID: 26004917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.